查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
COVID-19 治療藥物的全球市場 - 全球行業分析、規模、份額、增長、趨勢和預測，2022-2031 年
市場調查報告書
商品編碼
1229630

COVID-19 治療藥物的全球市場 - 全球行業分析、規模、份額、增長、趨勢和預測，2022-2031 年

COVID-19 Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
出版日期: | 出版商: Transparency Market Research | 英文 185 Pages | 商品交期: 2-10個工作天內

價格

該報告介紹了 2017 年至 2031 年全球 COVID-19 治療市場的收入，基準年為 2022 年，預測年為 2031 年。它還介紹了 2022 年至 2031 年全球 COVID-19 治療市場的複合年增長率 (CAGR %)。

本報告是廣泛研究的結果。在初步研究中，分析師對主要思想領袖、行業領袖和輿論製造者進行訪談，他們提供了大量的研究工作。在我們的二次研究中，我們參考了主要參與者的產品文獻、年度報告、新聞稿和相關文件，以瞭解 COVID-19療法市場。

該報告深入探討了全球 COVID-19 治療市場的競爭格局。已經確定了在全球 COVID-19 治療市場上運營的主要參與者，並根據各種屬性對每家公司進行了介紹。公司概況、財務狀況、近期發展和 SWOT 是本報告中描述的全球 COVID-19治療市場參與者的屬性。

目錄

第一章 前言

  • 市場定義和範圍
  • 市場細分
  • 主要研究目的
  • 調查亮點

第二章前提條件和研究方法

第 3 章執行摘要：COVID-19 治療藥物的全球市場

第四章市場概況

  • 介紹
    • 段定義
  • 概述
  • 市場動態
    • 促進者
    • 抑製劑
    • 機會
  • 2017-2031 年全球 COVID-19 治療藥物市場分析與預測
    • 市場收入預測

第 5 章關鍵見解

  • 技術進步
  • 解析管道
  • 區域/全球監管情景
  • COVID-19 影響分析

第 6 章 COVID-19 治療藥物的全球市場分析和預測：按藥物類別

  • 介紹和定義
  • 主要發現和發展
  • 2017-2031 年按藥物類別劃分的市場價值預測
    • 皮質類固醇
    • 抗病毒劑
    • 單克隆抗體
    • 激酶抑製劑
    • 其他（消炎藥、恢復期血漿、其他）
  • 市場吸引力：按藥物類別

第 7 章 COVID-19 藥物的全球市場分析和預測：按給藥途徑

  • 介紹和定義
  • 主要發現和發展
  • 2017-2031 年各給藥途徑的市場價值預測
    • 口服
    • 腸外
  • 市場吸引力：按給藥途徑

第 8 章 COVID-19 治療藥物的全球市場分析和預測：按分銷渠道

  • 介紹和定義
  • 主要發現和發展
  • 2017-2031 年各分銷渠道的市場價值預測
    • 醫院藥房
    • 零售藥店
    • 在線藥店
  • 市場吸引力：按分銷渠道

第 9 章 COVID-19 治療的全球市場分析和預測：按地區

  • 主要發現
  • 市場價值預測：按地區
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東/非洲
  • 市場吸引力：按國家/地區

第 10 章北美 COVID-19 治療市場分析與預測

  • 介紹
    • 主要發現
  • 2017-2031 年按藥物類別劃分的市場價值預測
    • 皮質類固醇
    • 抗病毒劑
    • 單克隆抗體
    • 激酶抑製劑
    • 其他（消炎藥、恢復期血漿、其他）
  • 2017-2031 年各給藥途徑的市場價值預測
    • 口服
    • 腸外
  • 2017-2031 年各分銷渠道的市場價值預測
    • 醫院藥房
    • 零售藥店
    • 在線藥店
  • 市場價值預測：按國家/地區劃分，2017-2031 年
    • 美國
    • 加拿大
  • 市場吸引力分析
    • 按治療等級
    • 按給藥途徑
    • 按分銷渠道
    • 按國家

第 11 章歐洲 COVID-19 治療市場分析與預測

  • 介紹
    • 主要發現
  • 2017-2031 年按藥物類別劃分的市場價值預測
    • 皮質類固醇
    • 抗病毒劑
    • 單克隆抗體
    • 激酶抑製劑
    • 其他（消炎藥、恢復期血漿、其他）
  • 2017-2031 年各給藥途徑的市場價值預測
    • 口服
    • 腸外
  • 2017-2031 年各分銷渠道的市場價值預測
    • 醫院藥房
    • 零售藥店
    • 在線藥店
  • 2017-2031 年按國家/次區域劃分的市場價值預測
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 歐洲其他地區
  • 市場吸引力分析
    • 按治療等級
    • 按給藥途徑
    • 按分銷渠道
    • 按國家/地區

第 12 章亞太 COVID-19 治療市場分析與預測

  • 介紹
    • 主要發現
  • 2017-2031 年按藥物類別劃分的市場價值預測
    • 皮質類固醇
    • 抗病毒劑
    • 單克隆抗體
    • 激酶抑製劑
    • 其他（消炎藥、恢復期血漿、其他）
  • 2017-2031 年各給藥途徑的市場價值預測
    • 口服
    • 腸外
  • 2017-2031 年各分銷渠道的市場價值預測
    • 醫院藥房
    • 零售藥店
    • 在線藥店
  • 2017-2031 年按國家/次區域劃分的市場價值預測
    • 中國
    • 日本
    • 印度
    • 澳大利亞/新西蘭
    • 亞太其他地區
  • 市場吸引力分析
    • 按治療等級
    • 按給藥途徑
    • 按分銷渠道
    • 按國家/地區

第 13 章拉丁美洲 COVID-19 治療市場分析與預測

  • 介紹
    • 主要發現
  • 2017-2031 年按藥物類別劃分的市場價值預測
    • 皮質類固醇
    • 抗病毒劑
    • 單克隆抗體
    • 激酶抑製劑
    • 其他（消炎藥、恢復期血漿、其他）
  • 2017-2031 年各給藥途徑的市場價值預測
    • 口服
    • 腸外
  • 2017-2031 年各分銷渠道的市場價值預測
    • 醫院藥房
    • 零售藥店
    • 在線藥店
  • 2017-2031 年按國家/次區域劃分的市場價值預測
    • 巴西
    • 墨西哥
    • 其他拉丁美洲地區
  • 市場吸引力分析
    • 按治療等級
    • 按給藥途徑
    • 按分銷渠道
    • 按國家/地區

第 14 章中東和非洲 COVID-19 治療市場分析與預測

  • 介紹
    • 主要發現
  • 2017-2031 年按藥物類別劃分的市場價值預測
    • 皮質類固醇
    • 抗病毒劑
    • 單克隆抗體
    • 激酶抑製劑
    • 其他（消炎藥、恢復期血漿、其他）
  • 2017-2031 年各給藥途徑的市場價值預測
    • 口服
    • 腸外
  • 2017-2031 年各分銷渠道的市場價值預測
    • 醫院藥房
    • 零售藥店
    • 在線藥店
  • 2017-2031 年按國家/次區域劃分的市場價值預測
    • 海灣合作委員會國家
    • 南非
    • 其他中東和南非
  • 市場吸引力分析
    • 按治療等級
    • 按給藥途徑
    • 按分銷渠道
    • 按國家/地區

第十五章競爭格局

  • 市場競爭對手 - 競爭矩陣（按層級，按公司規模）
  • 公司市場份額分析（2021 年）
  • 公司簡介
    • F. Hoffmann-La Roche Ltd
    • Gilead Sciences, Inc.
    • Eli Lilly and Company
    • Pfizer Inc.
    • Merck & Co., Inc.
    • GSK plc.
    • Celltrion Healthcare Co., Ltd.
    • Sorrento Therapeutics, Inc.
    • AstraZeneca
Product Code: TMRGL85370

The report provides revenue of the global COVID-19 therapeutics market for the period 2017-2031, considering 2022 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global COVID-19 therapeutics market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the COVID-19 therapeutics market.

The report delves into the competitive landscape of the global COVID-19 therapeutics market. Key players operating in the global COVID-19 therapeutics market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global COVID-19 therapeutics market profiled in this report.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global COVID-19 Therapeutics Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global COVID-19 Therapeutics Market Analysis and Forecasts, 2017 - 2031
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Technological Advancements
  • 5.2. Pipeline Analysis
  • 5.3. Regulatory Scenario by Region/globally
  • 5.4. COVID-19 Impact Analysis

6. Global COVID-19 Therapeutics Market Analysis and Forecast, by Drug Class

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Drug Class, 2017 - 2031
    • 6.3.1. Corticosteroids
    • 6.3.2. Anti-viral
    • 6.3.3. Monoclonal Antibodies
    • 6.3.4. Kinase Inhibitors
    • 6.3.5. Others (Anti-inflammatory Drugs, Convalescent Plasma, Others)
  • 6.4. Market Attractiveness, by Drug Class

7. Global COVID-19 Therapeutics Market Analysis and Forecast, by Route of Administration

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Route of Administration, 2017 - 2031
    • 7.3.1. Oral
    • 7.3.2. Parenteral
  • 7.4. Market Attractiveness, by Route of Administration

8. Global COVID-19 Therapeutics Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2017 - 2031
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
  • 8.4. Market Attractiveness, by Distribution Channel

9. Global COVID-19 Therapeutics Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness, by Country/Region

10. North America COVID-19 Therapeutics Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Drug Class, 2017 - 2031
    • 10.2.1. Corticosteroids
    • 10.2.2. Anti-viral
    • 10.2.3. Monoclonal Antibodies
    • 10.2.4. Kinase Inhibitors
    • 10.2.5. Others (Anti-inflammatory Drugs, Convalescent Plasma, Others)
  • 10.3. Market Value Forecast, by Route of Administration, 2017 - 2031
    • 10.3.1. Oral
    • 10.3.2. Parenteral
  • 10.4. Market Value Forecast, by Distribution Channel, 2017 - 2031
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Value Forecast, by Country, 2017 - 2031
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Drug Class
    • 10.6.2. By Route of Administration
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Europe COVID-19 Therapeutics Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Drug Class, 2017 - 2031
    • 11.2.1. Corticosteroids
    • 11.2.2. Anti-viral
    • 11.2.3. Monoclonal Antibodies
    • 11.2.4. Kinase Inhibitors
    • 11.2.5. Others (Anti-inflammatory Drugs, Convalescent Plasma, Others)
  • 11.3. Market Value Forecast, by Route of Administration, 2017 - 2031
    • 11.3.1. Oral
    • 11.3.2. Parenteral
  • 11.4. Market Value Forecast, by Distribution Channel, 2017 - 2031
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Retail Pharmacies
    • 11.4.3. Online Pharmacies
  • 11.5. Market Value Forecast, by Country/Sub-region, 2017 - 2031
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Italy
    • 11.5.5. Spain
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Drug Class
    • 11.6.2. By Route of Administration
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country/Sub-region

12. Asia Pacific COVID-19 Therapeutics Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Drug Class, 2017 - 2031
    • 12.2.1. Corticosteroids
    • 12.2.2. Anti-viral
    • 12.2.3. Monoclonal Antibodies
    • 12.2.4. Kinase Inhibitors
    • 12.2.5. Others (Anti-inflammatory Drugs, Convalescent Plasma, Others)
  • 12.3. Market Value Forecast, by Route of Administration, 2017 - 2031
    • 12.3.1. Oral
    • 12.3.2. Parenteral
  • 12.4. Market Value Forecast, by Distribution Channel, 2017 - 2031
    • 12.4.1. Hospital Pharmacies
    • 12.4.2. Retail Pharmacies
    • 12.4.3. Online Pharmacies
  • 12.5. Market Value Forecast, by Country/Sub-region, 2017 - 2031
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Drug Class
    • 12.6.2. By Route of Administration
    • 12.6.3. By Distribution Channel
    • 12.6.4. By Country/Sub-region

13. Latin America COVID-19 Therapeutics Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Drug Class, 2017 - 2031
    • 13.2.1. Corticosteroids
    • 13.2.2. Anti-viral
    • 13.2.3. Monoclonal Antibodies
    • 13.2.4. Kinase Inhibitors
    • 13.2.5. Others (Anti-inflammatory Drugs, Convalescent Plasma, Others)
  • 13.3. Market Value Forecast, by Route of Administration, 2017 - 2031
    • 13.3.1. Oral
    • 13.3.2. Parenteral
  • 13.4. Market Value Forecast, by Distribution Channel, 2017 - 2031
    • 13.4.1. Hospital Pharmacies
    • 13.4.2. Retail Pharmacies
    • 13.4.3. Online Pharmacies
  • 13.5. Market Value Forecast, by Country/Sub-region, 2017 - 2031
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Drug Class
    • 13.6.2. By Route of Administration
    • 13.6.3. By Distribution Channel
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa COVID-19 Therapeutics Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Drug Class, 2017 - 2031
    • 14.2.1. Corticosteroids
    • 14.2.2. Anti-viral
    • 14.2.3. Monoclonal Antibodies
    • 14.2.4. Kinase Inhibitors
    • 14.2.5. Others (Anti-inflammatory Drugs, Convalescent Plasma, Others)
  • 14.3. Market Value Forecast, by Route of Administration, 2017 - 2031
    • 14.3.1. Oral
    • 14.3.2. Parenteral
  • 14.4. Market Value Forecast, by Distribution Channel, 2017 - 2031
    • 14.4.1. Hospital Pharmacies
    • 14.4.2. Retail Pharmacies
    • 14.4.3. Online Pharmacies
  • 14.5. Market Value Forecast, by Country/Sub-region, 2017 - 2031
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & South Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Drug Class
    • 14.6.2. By Route of Administration
    • 14.6.3. By Distribution Channel
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 15.2. Market Share Analysis By Company (2021)
  • 15.3. Company Profiles
    • 15.3.1. F. Hoffmann-La Roche Ltd
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Financial Overview
      • 15.3.1.3. Product Portfolio
      • 15.3.1.4. Business Strategies
      • 15.3.1.5. Recent Developments
    • 15.3.2. Gilead Sciences, Inc.
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Financial Overview
      • 15.3.2.3. Product Portfolio
      • 15.3.2.4. Business Strategies
      • 15.3.2.5. Recent Developments
    • 15.3.3. Eli Lilly and Company
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Financial Overview
      • 15.3.3.3. Product Portfolio
      • 15.3.3.4. Business Strategies
      • 15.3.3.5. Recent Developments
    • 15.3.4. Pfizer Inc.
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Financial Overview
      • 15.3.4.3. Product Portfolio
      • 15.3.4.4. Business Strategies
      • 15.3.4.5. Recent Developments
    • 15.3.5. Merck & Co., Inc.
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Financial Overview
      • 15.3.5.3. Product Portfolio
      • 15.3.5.4. Business Strategies
      • 15.3.5.5. Recent Developments
    • 15.3.6. GSK plc.
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Financial Overview
      • 15.3.6.3. Product Portfolio
      • 15.3.6.4. Recent Developments
    • 15.3.7. Celltrion Healthcare Co., Ltd.
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Financial Overview
      • 15.3.7.3. Product Portfolio
      • 15.3.7.4. Business Strategies
      • 15.3.7.5. Recent Developments
    • 15.3.8. Sorrento Therapeutics, Inc.
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Financial Overview
      • 15.3.8.3. Product Portfolio
      • 15.3.8.4. Business Strategies
      • 15.3.8.5. Recent Developments
    • 15.3.9. AstraZeneca
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Financial Overview
      • 15.3.9.3. Product Portfolio
      • 15.3.9.4. Business Strategies
      • 15.3.9.5. Recent Developments

List of Tables

  • Table 01: Global COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 02: Global COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 03: Global COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel 2017-2031
  • Table 04: Global COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 05: North America COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 06: North America COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 07: North America COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 08: North America COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel 2017-2031
  • Table 09: Europe COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017-2031
  • Table 10: Europe COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 11: Europe COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 12: Europe COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel 2017-2031
  • Table 13: Asia Pacific COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 14: Asia Pacific COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 15: Asia Pacific COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 16: Asia Pacific COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel 2017-2031
  • Table 17: Latin America COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 18: Latin America COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 19: Latin America COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 20: Latin America COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 21: Middle East & Africa COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Middle East & Africa COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 23: Middle East & Africa COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 24: Middle East & Africa COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel 2017-2031

List of Figures

  • Figure 01: Global COVID-19 Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: COVID-19 Therapeutics Market Value Share, by Drug Class, 2021
  • Figure 03: COVID-19 Therapeutics Market Value Share, by Route of Administration, 2021
  • Figure 04: COVID-19 Therapeutics Market Value Share, by Distribution Channel, 2021
  • Figure 05: COVID-19 Therapeutics Market Value Share, by Region, 2021
  • Figure 06: Global COVID-19 Therapeutics Market Value Share Analysis, by Drug Class, 2021 and 2031
  • Figure 07: Global COVID-19 Therapeutics Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 08: Global COVID-19 Therapeutics Market Value (US$ Mn), by Corticosteroids, 2017-2031
  • Figure 09: Global COVID-19 Therapeutics Market Value (US$ Mn), by Anti-viral, 2017-2031
  • Figure 10: Global COVID-19 Therapeutics Market Value (US$ Mn), by Monoclonal Antibodies, 2017-2031
  • Figure 11: Global COVID-19 Therapeutics Market Value (US$ Mn), by Kinase Inhibitors, 2017-2031
  • Figure 12: Global COVID-19 Therapeutics Market Value (US$ Mn), by Others (Anti-inflammatory Drugs, Convalescent Plasma, Others) 2017-2031
  • Figure 13: Global COVID-19 Therapeutics Market Value Share Analysis, by Route of Administration, 2021 and 2031
  • Figure 14: Global COVID-19 Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 15: Global COVID-19 Therapeutics Market Value (US$ Mn), by Parenteral, 2017-2031
  • Figure 16: Global COVID-19 Therapeutics Market Value (US$ Mn), by Oral, 2017-2031
  • Figure 17: Global COVID-19 Therapeutics Market Value Share Analysis, by Distribution Channel 2021 and 2031
  • Figure 18: Global COVID-19 Therapeutics Market Attractiveness Analysis, by Distribution Channel 2022-2031
  • Figure 19: Global COVID-19 Therapeutics Market Revenue (US$ Mn), by Hospital Pharmacies, 2017-2031
  • Figure 20: Global COVID-19 Therapeutics Market Revenue (US$ Mn), by Retail Pharmacies, 2017-2031
  • Figure 21: Global COVID-19 Therapeutics Market Revenue (US$ Mn), by Online Pharmacies, 2017-2031
  • Figure 22: Global COVID-19 Therapeutics Market Value Share Analysis, by Region, 2021 and 2031
  • Figure 23: Global COVID-19 Therapeutics Market Attractiveness Analysis, by Region, 2022-2031
  • Figure 24: North America COVID-19 Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 25: North America COVID-19 Therapeutics Market Value Share Analysis, by Country, 2021 and 2031
  • Figure 26: North America COVID-19 Therapeutics Market Attractiveness Analysis, by Country, 2022-2031
  • Figure 27: North America COVID-19 Therapeutics Market Value Share Analysis, by Drug Class, 2021 and 2031
  • Figure 28: North America COVID-19 Therapeutics Market Attractiveness Analysis, by Drug Class 2022-2031
  • Figure 29: North America COVID-19 Therapeutics Market Value Share Analysis, by Route of Administration, 2021 and 2031
  • Figure 30: North America COVID-19 Therapeutics Market Attractiveness Analysis, by Route of Administration 2022-2031
  • Figure 31: North America COVID-19 Therapeutics Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 32: North America COVID-19 Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 33: Europe COVID-19 Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 34: Europe COVID-19 Therapeutics Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 35: Europe COVID-19 Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 36: Europe COVID-19 Therapeutics Market Value Share Analysis, by Drug Class, 2021 and 2031
  • Figure 37: Europe COVID-19 Therapeutics Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 38: Europe COVID-19 Therapeutics Market Value Share Analysis, by Route of Administration, 2021 and 2031
  • Figure 39: Europe COVID-19 Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 40: Europe COVID-19 Therapeutics Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 41: Europe COVID-19 Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 42: Asia Pacific COVID-19 Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 43: Asia Pacific COVID-19 Therapeutics Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 44: Asia Pacific COVID-19 Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 45: Asia Pacific COVID-19 Therapeutics Market Value Share Analysis, by Drug Class, 2021 and 2031
  • Figure 46: Asia Pacific COVID-19 Therapeutics Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 47: Asia Pacific COVID-19 Therapeutics Market Value Share Analysis, by Route of Administration, 2021 and 2031
  • Figure 48: Asia Pacific COVID-19 Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 49: Asia Pacific COVID-19 Therapeutics Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 50: Asia Pacific COVID-19 Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 51: Latin America COVID-19 Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 52: Latin America COVID-19 Therapeutics Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 53: Latin America COVID-19 Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 54: Latin America COVID-19 Therapeutics Market Value Share Analysis, by Drug Class, 2021 and 2031
  • Figure 55: Latin America COVID-19 Therapeutics Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 56: Latin America COVID-19 Therapeutics Market Value Share Analysis, by Route of Administration, 2021 and 2031
  • Figure 57: Latin America COVID-19 Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 58: Latin America COVID-19 Therapeutics Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 59: Latin America COVID-19 Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 60: Middle East & Africa COVID-19 Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 61: Middle East & Africa COVID-19 Therapeutics Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 62: Middle East & Africa COVID-19 Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 63: Middle East & Africa COVID-19 Therapeutics Market Value Share Analysis, by Drug Class, 2021 and 2031
  • Figure 64: Middle East & Africa COVID-19 Therapeutics Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 65: Middle East & Africa COVID-19 Therapeutics Market Value Share Analysis, by Route of Administration, 2021 and 2031
  • Figure 66: Middle East & Africa COVID-19 Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 67: Middle East & Africa COVID-19 Therapeutics Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 68: Middle East & Africa COVID-19 Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 69: Company Share Analysis